Othera Pharmaceuticals Presents New AMD Data at Angiogenesis 2007 Symposium

EXTON, Pa.--(BUSINESS WIRE)--Othera Pharmaceuticals, Inc. today announced that Dr. Shaker Mousa, Professor of Pharmacology and Executive Vice President and Chairman of the Pharmaceutical Research Institute at Albany College of Pharmacy presented new preclinical data demonstrating the potential for OT-551’s synergistic anti-angiogenic effect with either Lucentis or Avastin, the current standards of care for the wet form of age-related macular degeneration (wet AMD). Dr. Mousa’s talk was presented at the Angiogenesis 2007 Conference in Key Biscayne, FL, hosted by the Bascom Palmer Eye Institute.